| Literature DB >> 34215686 |
Michael P Gustafson1, Courtney M Wheatley-Guy2, Allison C Rosenthal3, Dennis A Gastineau4, Emmanuel Katsanis5, Bruce D Johnson2, Richard J Simpson6.
Abstract
The remarkable success of cancer immunotherapies has provided new hope to cancer patients. Unfortunately, a significant proportion of patients remain unable to respond to immunotherapy or maintain durable clinical responses. The lack of objective responses likely results from profound immune dysfunction often observed in patients with cancer. There is substantial evidence that exercise and physical activity can reduce incidence and improve outcomes in cancer patients. As the immune system is highly responsive to exercise, one potential avenue to improve immune function is through exercise and physical activity. A single event of dynamic exercise results in the substantial mobilization of leukocytes with increased functional capacities into the circulation. Chronic, or long-term, exercise leads to higher physical fitness in terms of greater cardiorespiratory function and/or muscle strength and endurance. High aerobic capacity, as measured by maximal oxygen uptake, has been associated with the reduction of dysfunctional T cells and improvements in the abundance of some T cell populations. To be sure, however, the mechanisms of exercise-mediated immune changes are both extensive and diverse. Here, we examine the evidence and theorize how acute and chronic exercise could be used to improve responses to cancer immunotherapies including immune checkpoint inhibitors, dendritic cell vaccines, natural killer cell therapies, and adoptive T cell therapies such as chimeric antigen receptor (CAR) T cells. Although the parameters of optimal exercise to yield defined outcomes remain to be determined, the available current data provide a compelling justification for additional human studies and clinical trials investigating the adjuvant use of exercise in immuno-oncology. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: immunocompetence; immunotherapy; translational medical research
Mesh:
Year: 2021 PMID: 34215686 PMCID: PMC8256759 DOI: 10.1136/jitc-2020-001872
Source DB: PubMed Journal: J Immunother Cancer ISSN: 2051-1426 Impact factor: 13.751
T cell phenotypes associated with physical conditions and improved by chronic exercise or exercise training
| T cell phenotype | Associated with obesity and/or physical inactivity | Associated with aging | Associated with chronic infection (ie, CMV) | Associated with physical fitness (VO2max) | References |
| CD3+ T cells | |||||
| CD8+ T cells | |||||
| CD4/CD8 ratio | |||||
| γδ T cells | |||||
| CD4+CD45RA+ | |||||
| CD8+CD45RA+CD27+CCR7+CD62L+ also KLRG-CD28+ | |||||
| CD4+CD45RO+ Memory | |||||
| CD8+CD45RO+ Memory T cells | |||||
| CD4+CD45RA–CCR7+ and CD8+CD45RA–CCR7+ | |||||
| CD4+CD45RA–CCR7– and CD8+CD45RA–CCR7– | |||||
| CD4+CD45RA+CCR7– and CD8+CD45RA+CCR7– | |||||
| CD4+CD25+Foxp3+ or CD127lo Regulatory T cells | |||||
| CD4+CD28–CD57+KLRG1+ and CD8+CD28-CD57+ KLRG1+ Senescent T cells | |||||
| CD4+PD-1+ |
↑indicates condition increases phenotype and ↓ indicates condition decreases phenotype.
*Indicates phenotype was not improved on in exercise by Duggal et al.71
CMV, cytomegalovirus; EMRA, effector memory RA +cells; PBMC, peripheral blood mononuclear cells; VO2max, maximal oxygen uptake.
Potential mechanisms that could be employed to improve responses to immunotherapy via exercise
| Immunotherapy | Mode of exercise | Potential mechanisms to support immunotherapy |
| Immune checkpoint inhibitors | Acute/training | Increase in trafficking and homing of T cells to tumors |
| Chronic/long term | Diminish the presence of senescent T cells | |
| Adoptive, CAR, and γδ T cell Therapies | Acute/training | Increase in T cell numbers, including low frequency viral or antigen specific T cells, for ex vivo expansion |
| Chronic/long term | Maintain homeostatic mechanisms for naïve T cell survival via IL-7 | |
| NK Cell Therapies | Acute/training | Increase in cell numbers for ex vivo expansion |
| Chronic/long term | Prevent obesity-mediated NK cell dysfunction | |
| Cancer vaccines: | Acute/training | Increase in cell yield from leukapheresis products |
| Chronic/long term | Improve maintenance of circulating DCs normally lost during aging |
DCs, dendritic cells; NK, natural killer; TME, tumor microenvironment.